Dyax Corp. has announced financial results for the first quarter ended March 31, 2015. Recent highlights include:
- Reported positive safety, pharmacokinetic, biomarker and proof-of-concept efficacy results from the Phase 1b study of DX-2930 in HAE patients;
- Receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for the investigation of DX-2930 for HAE;
- Kalbitor net sales were $16.0 million for the first quarter of 2015.
“Dyax achieved several milestones in the early months of 2015,” said Gustav Christensen, President and CEO of Dyax. “DX-2930, our lead development candidate being investigated for the prevention of HAE attacks, demonstrated impressive Phase 1b results. This study provided important clinical proof-of-concept, dose response and safety information in HAE patients. The Kalbitor business continue to generate cash flow which supports our development programs. We have made tremendous progress at Dyax and are well positioned for long-term growth.”
(Source: Dyax Corp.)